Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VIVO

Meridian Bioscience (VIVO) Stock Price, News & Analysis

Meridian Bioscience logo

About Meridian Bioscience Stock (NASDAQ:VIVO)

Advanced Chart

Key Stats

Today's Range
$33.97
$33.97
50-Day Range
$33.00
$33.97
52-Week Range
$20.35
$34.38
Volume
N/A
Average Volume
973,737 shs
Market Capitalization
$1.50 billion
P/E Ratio
35.02
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

VIVO Stock News Headlines

Meridian Bioscience Inc (VIVO)
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Meridian Growth Legacy MERDX
Biomerica, Inc. (BMRA)
See More Headlines

VIVO Stock Analysis - Frequently Asked Questions

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its earnings results on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.03. The company had revenue of $76.20 million for the quarter, compared to analysts' expectations of $68.40 million. Meridian Bioscience had a trailing twelve-month return on equity of 16.74% and a net margin of 12.70%.

Meridian Bioscience subsidiaries include these companies: Exalenz Bioscience.

Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/12/2021
Today
4/19/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:VIVO
Employees
702
Year Founded
1977

Profitability

Trailing P/E Ratio
35.02
Forward P/E Ratio
40.93
P/E Growth
N/A
Net Income
$42.46 million
Pretax Margin
16.31%

Debt

Sales & Book Value

Annual Sales
$333.02 million
Cash Flow
$1.78 per share
Price / Cash Flow
19.13
Book Value
$8.41 per share
Price / Book
4.04

Miscellaneous

Free Float
42,996,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.23

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:VIVO) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners